Loading...
Trametinib: A Targeted Therapy in Metastatic Melanoma
Trametinib is a MEK inhibitor approved both as a single agent and in combination with dabrafenib for the treatment of BRAF V600E or V600K mutated melanoma. It is a once-daily oral medication that was approved based on progression-free survival and overall survival advantage compared to chemotherapy....
Na minha lista:
| Udgivet i: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Harborside Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6570520/ https://ncbi.nlm.nih.gov/pubmed/31249721 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|